325 related articles for article (PubMed ID: 30485408)
21. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma.
Hartmann S; Eichenauer DA
Pathology; 2020 Jan; 52(1):142-153. PubMed ID: 31785822
[TBL] [Abstract][Full Text] [Related]
22. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
Lazarovici J; Dartigues P; Brice P; Obéric L; Gaillard I; Hunault-Berger M; Broussais-Guillaumot F; Gyan E; Bologna S; Nicolas-Virelizier E; Touati M; Casasnovas O; Delarue R; Orsini-Piocelle F; Stamatoullas A; Gabarre J; Fornecker LM; Gastinne T; Peyrade F; Roland V; Bachy E; André M; Mounier N; Fermé C
Haematologica; 2015 Dec; 100(12):1579-86. PubMed ID: 26430172
[TBL] [Abstract][Full Text] [Related]
23. [Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma].
Dourthe ME; Simonin M; Rigaud C; Haouy S; Montravers F; Ducou Le Pointe H; Garnier N; Minard-Colin V; Jo Molina T; Boudjemaa S; Leblanc T; Landman-Parker J
Bull Cancer; 2023 Sep; 110(9):968-977. PubMed ID: 37062647
[TBL] [Abstract][Full Text] [Related]
24. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
Binkley MS; Rauf MS; Milgrom SA; Pinnix CC; Tsang R; Dickinson M; Ng AK; Roberts KB; Gao S; Balogh A; Ricardi U; Levis M; Casulo C; Stolten M; Specht L; Plastaras JP; Wright C; Kelsey CR; Brady JL; Mikhaeel NG; Hoppe BS; Terezakis SA; Picardi M; Della Pepa R; Kirova Y; Akhtar S; Maghfoor I; Koenig JL; Jackson C; Song E; Sehgal S; Advani RH; Natkunam Y; Constine LS; Eich HT; Wirth A; Hoppe RT
Blood; 2020 Jun; 135(26):2365-2374. PubMed ID: 32211877
[TBL] [Abstract][Full Text] [Related]
25. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA; Engert A
Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up of 2 patients treated with
Golstein SC; Muylle K; Vercruyssen M; Spilleboudt C; de Wind A; Bron D
Eur J Haematol; 2018 Sep; 101(3):415-417. PubMed ID: 29719928
[TBL] [Abstract][Full Text] [Related]
27. [Nodular lymphocyte-predominant Hodgkin's lymphoma: Principles of diagnosis and treatment].
Moiseeva TN; Al-Radi LS; Kovrigina AM; Goryacheva SR; Julakyan UL; Margolin OV; Skidan NI; Tseytlina MA; Kravchenko SK
Ter Arkh; 2015; 87(11):78-83. PubMed ID: 26821421
[TBL] [Abstract][Full Text] [Related]
28. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I
Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917
[TBL] [Abstract][Full Text] [Related]
29. Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis.
Churchill HR; Roncador G; Warnke RA; Natkunam Y
Hum Pathol; 2010 Dec; 41(12):1726-34. PubMed ID: 20825974
[TBL] [Abstract][Full Text] [Related]
30. GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities.
Kezlarian B; Alhyari M; Venkataraman G; Karner K; Inamdar KV; Menon MP
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):180-184. PubMed ID: 28877074
[TBL] [Abstract][Full Text] [Related]
31. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292
[TBL] [Abstract][Full Text] [Related]
32. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Borchmann S; Joffe E; Moskowitz CH; Zelenetz AD; Noy A; Portlock CS; Gerecitano JF; Batlevi CL; Caron PC; Drullinsky P; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Moskowitz AJ; Owens CN; Palomba ML; Younes A; Straus DJ
Blood; 2019 May; 133(20):2121-2129. PubMed ID: 30770396
[TBL] [Abstract][Full Text] [Related]
33. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
[TBL] [Abstract][Full Text] [Related]
34. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.
Hartmann S; Schuhmacher B; Rausch T; Fuller L; Döring C; Weniger M; Lollies A; Weiser C; Thurner L; Rengstl B; Brunnberg U; Vornanen M; Pfreundschuh M; Benes V; Küppers R; Newrzela S; Hansmann ML
Leukemia; 2016 Apr; 30(4):844-53. PubMed ID: 26658840
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA; Fuchs M; Pluetschow A; Klimm B; Halbsguth T; Böll B; von Tresckow B; Nogová L; Borchmann P; Engert A
Blood; 2011 Oct; 118(16):4363-5. PubMed ID: 21828141
[TBL] [Abstract][Full Text] [Related]
36. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Moore EM; Swerdlow SH; Gibson SE
Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
[TBL] [Abstract][Full Text] [Related]
37. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Mocikova H; Pytlik R; Stepankova P; Michalka J; Markova J; Koren J; Buresova L; Raida L; Kral Z
Acta Haematol; 2015; 134(3):187-92. PubMed ID: 26021284
[TBL] [Abstract][Full Text] [Related]
38. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.
Biasoli I; Stamatoullas A; Meignin V; Delmer A; Reman O; Morschhauser F; Coiffier B; Bosly A; Diviné M; Brice P
Cancer; 2010 Feb; 116(3):631-9. PubMed ID: 20029973
[TBL] [Abstract][Full Text] [Related]
39. Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?
Barber NA; Loberiza FR; Perry AM; Bast M; Holdeman KP; Esfahane AB; Weisenburger DD; Vose J; Bierman P; Armitage JO; Bociek RG
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):392-7. PubMed ID: 23773450
[TBL] [Abstract][Full Text] [Related]
40. Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease?
Hartmann S; Döring C; Jakobus C; Rengstl B; Newrzela S; Tousseyn T; Sagaert X; Ponzoni M; Facchetti F; de Wolf-Peeters C; Steidl C; Gascoyne R; Küppers R; Hansmann ML
PLoS One; 2013; 8(11):e78812. PubMed ID: 24244368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
